(Q41063702)

26 September 2017

title

HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination (English)

1 reference

26 September 2017

0 references

Yusa K

1

1 reference

26 September 2017

Kavlick MF

series ordinal

2

1 reference

26 September 2017

Kosalaraksa P

series ordinal

3

1 reference

26 September 2017

Mitsuya H

series ordinal

4

1 reference

26 September 2017

publication date

1 December 1997

1 reference

26 September 2017

1 reference

26 September 2017

volume

36

1 reference

26 September 2017

issue

3

1 reference

26 September 2017

page(s)

179-189

1 reference

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

HIV resistance to reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

DNA recombination during PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

1 reference

7 January 2021

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

The accuracy of reverse transcriptase from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

HIV-1 sensitivity to zidovudine and clinical outcome in children

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900053-3

7 January 2021

10.1016/S0166-3542(97)00053-3

Identifiers

DOI

1 reference

26 September 2017

1 reference